Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 05/23 05:35:04 pm
65.6 EUR   -0.79%
05/23UCB : U.S. Court of Appeals confirms validity of patent for …
05/10UCB : The comeback of an upward trend can be anticipated
05/08UCB : Proxy Statments
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

UCB : Transparency notification of Vanguard Health Care Fund

share with twitter share with LinkedIn share with facebook
share via e-mail
04/11/2012 | 08:41pm CEST

Participation on March 30, 2012 (according to Article 6 of the law of May 2, 2007 on the disclosure of large shareholdings).

Brussels (Belgium), April 11, 2012 - 7.30 p.m. (CET) - regulated information - Vanguard Health Care Fund (having its registered offices c/o The Vanguard Group, 455 Devon Park Drive, Wayne, PA 19087 - USA) acquired 5,821,811 UCB shares with voting rights (on a total number of 183,365,052) on March 30, 2012, representing 3.17% of UCB's share capital, which means that Vanguard Health Care Fund crossed the threshold of notification of 3%.

UCB S.A. - Allée de la Recherche, 60 - 1070 Brussels - RPM 0403.053.608

For further information

Antje Witte, Investor Relations, UCB

T +32.2.559.9414, [email protected]

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

UCB Forward-looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on UCB
05/23UCB : U.S. Court of Appeals confirms validity of patent for …
05/08UCB : Proxy Statments
05/03UCB, Science 37 to conduct virtual clinical trials
04/27UCB : Announces Positive CHMP Opinion for CIMZIA® (certolizumab pegol) in &helli..
04/27UCB : Ex-dividend day for final dividend
04/26UCB : General Meeting of Shareholders
04/05UCB : Patent Issued for Treatment for Bone Diseases (USPTO 9925260)
04/04UCB : Transparency notification The Capital Group Companies Inc
04/04UCB : Acquisition of own shares
More news
News from SeekingAlpha
05/17YOUR DAILY PHARMA SCOOP : Loxo Outstanding Results, Cimzia Trial Success, Audent.. 
05/16UCB's Cimzia successful in late-stage study in subtype of ankylosing spondyli.. 
04/27European advisory group April meeting results 
02/23UCB S.A. 2017 Q4 - Results - Earnings Call Slides 
02/22UCB S.A. reports FY results 
Financials (€)
Sales 2018 4 515 M
EBIT 2018 1 101 M
Net income 2018 756 M
Finance 2018 121 M
Yield 2018 1,88%
P/E ratio 2018 16,33
P/E ratio 2019 14,53
EV / Sales 2018 2,82x
EV / Sales 2019 2,63x
Capitalization 12 861 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Technical analysis trends UCB
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 21
Average target price 68,8 €
Spread / Average Target 4,1%
EPS Revisions
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB-1.03%15 133
JOHNSON & JOHNSON-11.45%329 663
PFIZER-1.16%208 947
NOVARTIS-6.55%201 263
ROCHE HOLDING LTD.-8.90%194 670